Project Details
Project Description
This is a retrospective study using real-world data collected through the ANZ and APAC Myeloma and Related Diseases Registry (MRDR) to investigate the prognostic impact of 1q21 gain and 1q21 amp in RRMM patients treated with daratumumab
| Short title | 1Q Dara study |
|---|---|
| Status | Not started |